Have a feature idea you'd love to see implemented?
Let us know!
RGLS Regulus Therapeutics Inc
Price (delayed)
$1.655
Market cap
$108.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.25
Enterprise value
$91.84M
Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop
Highlights
RGLS's debt has dropped by 84% year-on-year and by 52% since the previous quarter
RGLS's EPS is up by 26% year-on-year and by 14% since the previous quarter
Regulus Therapeutics's equity has soared by 189% YoY but it has decreased by 9% from the previous quarter
Regulus Therapeutics's net income has decreased by 24% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of RGLS
Market
Valuations
Earnings
Shares outstanding
65.47M
Market cap
$108.35M
Enterprise value
$91.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$35M
EBITDA
-$34.7M
Free cash flow
-$33.7M
Per share
Balance sheet
Liquidity
EPS
-$1.25
Free cash flow per share
-$0.52
Book value per share
$1.5
Revenue per share
$0
TBVPS
$1.61
Total assets
$104.12M
Total liabilities
$5.94M
Debt
$675,000
Equity
$98.18M
Working capital
$95.08M
Debt to equity
0.01
Current ratio
19.06
Quick ratio
17.96
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-49.4%
Return on equity
-55.5%
Return on invested capital
-82.2%
Return on capital employed
-35.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGLS stock price
How has the Regulus Therapeutics stock price performed over time
Intraday
2.8%
1 week
13.36%
1 month
5.41%
1 year
32.4%
YTD
29.3%
QTD
5.41%
Financial performance
How have Regulus Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$37.51M
Net income
-$35.39M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 29% year-on-year and by 15% since the previous quarter
Regulus Therapeutics's net income has decreased by 24% YoY and by 13% from the previous quarter
Growth
What is Regulus Therapeutics's growth rate over time
Valuation
What is Regulus Therapeutics stock price valuation
P/E
N/A
P/B
1.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RGLS's EPS is up by 26% year-on-year and by 14% since the previous quarter
Regulus Therapeutics's equity has soared by 189% YoY but it has decreased by 9% from the previous quarter
The stock's price to book (P/B) is 24% less than its 5-year quarterly average of 1.4 and 18% less than its last 4 quarters average of 1.3
Efficiency
How efficient is Regulus Therapeutics business performance
The ROIC has soared by 63% YoY and by 40% from the previous quarter
Regulus Therapeutics's return on equity has increased by 35% YoY and by 16% QoQ
RGLS's return on assets is up by 22% year-on-year and by 11% since the previous quarter
Dividends
What is RGLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGLS.
Financial health
How did Regulus Therapeutics financials performed over time
Regulus Therapeutics's total assets has surged by 139% YoY but it has decreased by 9% QoQ
RGLS's total liabilities is down by 38% YoY and by 9% QoQ
RGLS's debt is 99% smaller than its equity
Regulus Therapeutics's equity has soared by 189% YoY but it has decreased by 9% from the previous quarter
The debt to equity has plunged by 92% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.